Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Andexxa
Pharma
AZ's bleeding reversal agent Andexxa meets trial endpoint early
The phase 4 study ended ahead of schedule after it quickly established the benefits of Andexxa. AZ now plans to seek full approvals for the drug.
Zoey Becker
Jun 5, 2023 1:53pm
Alexion gives updated look at what AZ's getting for $39B
Jan 12, 2021 11:20am
Alexion bets $1.4B on Portola's laggard bleeding drug Andexxa
May 5, 2020 11:08am
Production of Portola's Andexxa underway—News of Note
Feb 7, 2019 12:00am
Portola finally wins FDA nod for commercial production of Adexxa
Jan 2, 2019 10:33am
Portola hires Glenn Brame to oversee manufacturing
Jun 26, 2018 9:57am
